A J.P. Morgan projection sees the diabetes and weight-loss drug market in India, China, and Brazil tripling to $22 billion by 2035. While this signals long-term growth, investors should track factors like drug affordability, manufacturing complexity, and local market adoption rates for firms like Torrent Pharmaceuticals and Divi's Laboratories.
The global demand for GLP-1 agonists, a class of drugs used for weight loss and diabetes management, is increasingly focusing on emerging economies. A new analysis by J.P. Morgan suggests that the combined market for these treatments in China, India, and Brazil could grow from its current value of $6.6 billion to $22 billion by 2035. This potential expansion represents a significant shift for the pharmaceutical sector in these regions, which have historically seen much lower usage rates of these advanced therapies compared to the United States.
For Indian pharmaceutical companies, this trend highlights a potential long-term opportunity to serve a massive patient population. However, the path to market leadership involves more than just increasing supply. Currently, market penetration for these treatments in India remains below 0.2%, reflecting a significant gap that needs to be bridged before mass-market adoption can occur.
In the context of potential market beneficiaries, analysts have highlighted firms with strong domestic or technical footprints. Divi's Laboratories, which is a major manufacturer of Active Pharmaceutical Ingredients (APIs), is seen as a potential player given the complex manufacturing requirements for these drugs. If the company successfully adapts its production capabilities to meet the high technical standards required for GLP-1 peptide synthesis, it could become a significant part of the supply chain. On the other hand, Torrent Pharmaceuticals, with its established focus on chronic therapies such as diabetes and cardiology, may look to expand its portfolio to include these newer treatments as they become more accessible.
Investors must also consider the significant hurdles that exist for this sector. GLP-1 drugs are fundamentally different from standard generic medicines, as they often require complex injectable delivery systems and involve difficult chemical manufacturing processes. Affordability is another major barrier. In India, the success of these products will likely depend on future patent expirations, potential government-led price negotiations, and the ability of firms to make these treatments cost-effective for the local population. Furthermore, there is a cultural preference for oral pills over injectables in many parts of the country, which could slow the rate of adoption.
Moving forward, the sector’s growth will not be immediate or guaranteed. Investors may monitor several key areas: whether domestic firms can secure partnerships for local manufacturing, how regulatory bodies handle patent and pricing issues, and the speed at which the Indian healthcare system incorporates these specialized drugs into mainstream treatment protocols. The transition from a niche, high-cost therapy to a widely accessible drug will require significant investment in both production and distribution infrastructure.